Cite
HARVARD Citation
Kostapanos, M. et al. (n.d.). Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale. Journal of drug assessment. pp. 167-174. [Online].